Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Accelerated progression of IDH mutant glioma after first recurrence

15 Jan 2019

Abstract excerpt

BACKGROUND: Isocitrate dehydrogenase (IDH) mutant gliomas are a distinct subtype, reflected in the World Health Organization (WHO) 2016 revised diagnostic criteria. To inform IDH-targeting trial design, we sought to characterize outcomes exclusively within IDH mutant gliomas. METHODS: We retrospectively analyzed 275 IDH mutant glioma patients treated at our institution. Progression was determined using low-grade...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neurofibromatosis and Schwannoma Cases
Share to Glioma Diagnosis and Treatment
Share to Meningioma and schwannoma management

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30668823
DOI: 10.1093/neuonc/noz016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Accelerated progression of IDH mutant glioma after first recurrencePMID 30668823Read ↗

Do the benefits of IDH mutations in high-grade glioma persist beyond the first recurrence? A multi-institutional retrospective analysisSemantic proximity Read ↗

Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.Semantic proximity Read ↗

Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.Semantic proximity Read ↗

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.Semantic proximity Read ↗

Glioma progression is shaped by genetic evolution and microenvironment interactions.Semantic proximity Read ↗

Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution.Semantic proximity Read ↗

Prognostic relevance of resection at first recurrence in isocitrate dehydrogenase mutant lower-grade glioma: results from a retrospective, single-center, volumetric analysis.Semantic proximity Read ↗

Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.Semantic proximity Read ↗

Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma.Semantic proximity Read ↗

Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant gliomaSemantic proximity Read ↗

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaSemantic proximity Read ↗

Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.